Answers are grounded in this paper and cite their sources.
NanoReady is a next-generation mRNA delivery platform designed to overcome the limitations of conventional lipid-based systems, such as lipid nanoparticles (LNP) and Lipoplex (LPX), particularly for personalized cancer vaccines. It combines a novel cationic lipid with a biodegradable polymer, forming a stable nanoparticle that efficiently encapsulates mRNAs with a wide range of lengths. NanoReady nanoparticles can be pre-assembled without RNA as a ready-made formulation, and upon availability of patient-specific antigen-encoding mRNA, NanoReady rapidly incorporates the RNA to form uniform, administration-ready particles. NanoReady selectively delivers antigen mRNA to professional antigen-presenting cells, particularly dendritic cells in the spleen, where robust antigen-specific T-cell responses are elicited. When combined with mRNA, NanoReady forms multilamellar nanoparticles that exhibit high mRNA loading capacity and efficient endosomal release, leading to enhanced protein expression. As a result, it induces strong T-cell immune responses to the encoding antigen that overcomes immune tolerance when encoding self-antigens. In B16-F10 tumor mouse model, NanoReady mRNA vaccine encoding the self-antigen mTRP2 induced potent CD8 T-cell responses, resulting in significant tumor growth suppression and improved survival. Compared to DOTMA based LPX formulations, NanoReady achieved markedly higher antigen expression, stronger antigen-specific T cell immunogenicity, and superior anti-tumor efficacy. Importantly, a pilot non-human primate (NHP) study demonstrated antigen-specific T-cell immunogenicity following NanoReady-mRNA vaccination, supporting translational potential. Furthermore, repeated administration of NanoReady-mRNA vaccine showed no toxicity in various animal models confirming the platform's high biocompatibility and safety. These findings highlight NanoReady as a promising platform for personalized cancer vaccines, combining high mRNA delivery efficiency, robust immune response, and excellent safety.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: